BioPharma Credit PLC
20 August 2026
20 August 2026
BIOPHARMA CREDIT PLC
(THE "COMPANY")
COMPLETION OF SALE OF STAKE IN LUMIRA COLOMBIA
Recovery of 101 per cent. of principal investment[1]
BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investment trust, is pleased to announce that on 14 August 2026 it completed the sale of its indirect interest in Lumira SAS (Colombia) ("Lumira Colombia"), a Colombian distributor of third-party diagnostic products. The successful closing of the sale marks the conclusion of the US$419 million investment originally made by the Company and BioPharma Credit Investments V (Master) LP ("BioPharma-V") in the LumiraDx group companies commencing in March 2021.
Taking into account the proceeds received from the sale of Lumira Colombia, the proceeds received when LumiraDx sold its point-of-care diagnostics platform business and certain related assets to Roche Diagnostics Limited in July 2024, and the cash interest received over time from LumiraDx group companies, the Company has recovered approximately 101 per cent. of its principal investment1, on a gross and net basis.
LumiraDx Colombia Holdings Limited, the former UK parent entity of Lumira Colombia and the entity in which the Company and BioPharma-V held its indirect interests, will be wound-up in due course.
Enquiries:
BioPharma Credit plc
via MUFG Corporate Governance Limited
Company Secretary
+44 (0) 333 300 1932
Burson Buchanan
Henry Wilson / Helen Tarbet / Jamie Hooper / Nick Croysdill
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit PLC is London's only specialist debt investor to the life sciences industry and joined the LSE in March 2017. BioPharma Credit PLC seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. BioPharma Credit PLC seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.
[1] As used herein, the recovery of principal investment is equivalent to the multiple of invested capital, and excludes all expected expenses and wind-down costs. For more information as to how the Company calculates its gross and net multiple of invested capital, please refer to the disclaimer on page 1 of the Company's investor presentation dated 20 April 2026, available on the Company's website (https://bpcruk.com/company-presentation-april-2026/). Past performance is not an indication of future performance.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.